Market Update - Bull SA issues preferred share to the French State to protect national interests in relation to sovereign sensitive activities carried out by Atos Press Release Market update Bull SA issues preferred share to the French State to protect national interests in relation to sovereign sensitive activities carried out by Atos Paris, France – November 8, 2024 – Further to the agreement announced on June 26, 2024 between Atos SE (“Atos”), Bull SA and the French State, Atos announces that Bull SA has issued today a preferred share (action de préférence) for the benefit of the Fren...
Point de Marché - Emission par Bull SA d’une action de préférence au profit de l’Etat français dans le cadre des droits de protection accordés à l’Etat français sur les activités souveraines et sensibles Communiqué de presse Point de marché Emission par Bull SA d’une action de préférence au profit de l’Etat français dans le cadre des droits de protection accordés à l’Etat français sur les activités souveraines et sensibles Paris, France – 8 Novembre 2024 – Dans le prolongement de la convention conclue entre Atos SE (« Atos »), Bull SA et l’Etat français le 26 juin 2024, Atos annonce que ...
In this report we evaluate spreads in the TMT hybrids space. Over the year, TMT hybrid notes have performed well. However, we now think the tightening potential over senior notes is more limited. One can move up in quality (or lower duration) without giving up much additional spread.
>Atos launches the € 233m capital increase dedicated to shareholders, with preferential subscription rights … - Atos announces this morning the launch of a capital increase with preferential subscription rights for shareholders, for a gross amount, including issue premium, of € 233.3m through the issuance of 63.06bn new shares, with a subscription price of € 0.0037 per new share (i.e. 13,497 new shares for 24 existing shares) and a subscription period from 14 November...
>Atos launches the € 233m capital increase dedicated to shareholders, with preferential subscription rights … - Atos announces this morning the launch of a capital increase with preferential subscription rights for shareholders, for a gross amount, including issue premium, of € 233.3m through the issuance of 63.06bn new shares, with a subscription price of € 0.0037 per new share (i.e. 13,497 new shares for 24 existing shares) and a subscription period from 14 November...
>Apparently no major surprises in Q3... - Nexi just released its Q3 2024 results.Organic growth in sales and EBITDA came to +5.1% and +6.2% respectively, down compared to previous quarters (sales/EBITDA: Q2 = +5.8/7.5% and Q1 = +6.0/8.6%) but close to expectations (sales/EBITDA: ODDO BHF = +4.8/6.5% and consensus = +4.8/6.2%).The Merchant Solutions division continues to drive the group's growth (+6.6% vs +2.8% for Issuing Solutions and +3.6% for Digital Bank...
>Q3 2024 results 13% above company compiled css - IAG released a strong set of Q3 2024 results with operating profit reported at € 2.013bn (+15% y-o-y), 19% above our estimates and 13% above company compiled consensus. This positive operational performance comes on the back of strong demand on all core markets leading to a passenger unit revenue increase of 1.2% (vs. our virtually flat expectation of 0.3%) despite an exceptionally strong comps and a capacity gr...
>Q3 2024 results 13% above company compiled css - IAG released a strong set of Q3 2024 results with operating profit reported at € 2.013bn (+15% y-o-y), 19% above our estimates and 13% above company compiled consensus. This positive operational performance comes on the back of strong demand on all core markets leading to a passenger unit revenue increase of 1.2% (vs. our virtually flat expectation of 0.3%) despite an exceptionally strong comps and a capacity gr...
3Q'24 vs. 3Q'23 Results Sales: € 9.329 Bn (+7.9% vs. +6.1% BS(e) and n/a consensus); EBIT: € 2.013 Bn (+15.4% vs. +4.8% BS(e) and +1.8% consensus); 9M'24 vs. 9M'23 Results Sales: € 24.053 Bn (+8.2% vs. +7.5% BS(e) and n/a consensus); EBIT: € 3.322 Bn (+10.5% vs. +4.4% BS(e) and +2.7% consensus);
>Un T3 sans surprise majeure a priori… - Nexi vient de publier ses résultats T3 2024.Les croissances organiques de CA et d’EBITDA ressortent respectivement à +5.1% et +6.2%, en ralentissement par rapport aux trimestres précédents (CA/EBITDA : T2 = +5.8/7.5% et T1 = +6.0/8.6%) mais proches des attentes (CA/EBITDA : ODDO BHF = +4.8/6.5% et consensus = +4.8/6.2%).La division Merchant Solutions continue de tirer la croissance du groupe (+6.6% vs +2.8% pour Issui...
Rdos. 3T'24 vs 3T'23: Ventas: 9.329 M euros (+7,9% vs +6,1% BS(e) y n/a consenso); EBIT: 2.013 M euros (+15,4% vs +4,8% BS(e) y +1,8% consenso). Rdos. 9meses'24 vs 9meses'23: Ventas: 24.053 M euros (+8,2% vs +7,5% BS(e) y n/a consenso); EBIT: 3.322 M euros (+10,5% vs +4,4% BS(e) y +2,7% consenso).
>Biopharma sales momentum improves… - Sales grew by +12% or +12% cc (vs +9% cc in Q2) to € 1.8bn (in line). Momentum improved sequentially and unlike Q2, where it was mostly explained by Bio-supplies/Diagnostic, it is now Biopharma leading the growth (+12%cc in Q3 vs +9% in Q2). Bio Supplies (+49% cc in Q3 vs +93% in Q2) deteriorated sequentially yet maintained a very solid pace. Diagnostic (+1% cc in Q3 vs +1% in Q2) kept the very modest pace seen in Q2 (-3% cc in Q3...
>Start of positive momentum in residential property development - Altarea reported for 9M 2024 sales at € 1,663.8m, down 8.4% y-o-y and relatively close to our forecasts (€ 1,638m est.). This performance mainly reflects the transition period that residential property development is currently navigating, noting that: 1/ Altarea thinks that it has now set down the foundations of its new production tool for an upturn that could materialise in 2025-2026 and that; 2/ the ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.